Investigation and comparison of antimullerin hormone in patients with tubal ectopic pregnancy treated with methotrexate and laparoscopy.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240514061800N4

Enrollment

Registered

2024-08-21

Start date

2024-09-10

Completion date

Unknown

Last updated

2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ectopic Pregnancy. Ectopic pregnancy

Interventions

Intervention 1: Intervention group: Patients are treated with methotrexate at a dose of 1 mg/kg as a single dose. Intervention 2: Intervention group: Patients undergo laparoscopic surgery.

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Adult women 18-40 years old Patients who do not have any relative or absolute contraindications for using methotrexate Absence of liver failure Not suffering from chronic renal failure with GFR less than 30 mL/min No lung diseases, stomach ulcers and immune deficiencies

Exclusion criteria

Exclusion criteria: The patient's lack of consent to continue participating in the study Incidence of complications related to methotrexate in the group treated with methotrexate

Design outcomes

Primary

Measure	Time frame
Evaluation of the level of antimullerin hormone. Timepoint: Before, 3 and 6 months after the intervention. Method of measurement: Biochemical tests.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarzieh Agha Hosseini

Tehran University of Medical Sciences

ivfshariati69@gmail.com+98 21 8800 8810

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026